Nicholas B Sobol1, Joshua A Korsen1,2, Ali Younes3, Kimberly J Edwards1, Jason S Lewis4,5,6,7. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA. 3. Department of Chemistry, Hunter College, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org. 5. Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA. lewisj2@mskcc.org. 6. Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org. 7. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. lewisj2@mskcc.org.
Abstract
PURPOSE: Targeted delivery in vivo remains an immense roadblock for the translation of nanomaterials into the clinic. The greatest obstacle is the mononuclear phagocyte system (MPS), which sequesters foreign substances from general circulation and causes accumulation in organs such as the liver and spleen. The purpose of this study was to determine whether attaching an active targeting antibody, 5B1, to the surface of gold nanoparticles and using clodronate liposomes to deplete liver and splenic macrophages could help to minimize uptake by MPS organs, increase targeted delivery to CA19.9-positive pancreatic tumors, and enhance pancreatic tumor delineation. PROCEDURES: To produce the antibody-gold nanoparticle conjugate (Ab-AuNP), the Ab was conjugated to p-isothiocyanatobenzyl-desferrioxamine (p-SCN-DFO) and subsequently conjugated to NHS-activated gold nanoparticles. The Ab-AuNP was characterized by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Modified Lindmo assay was performed to assess binding affinity and internalization potential in vitro. The Ab-AuNP was radiolabeled with 89Zr and injected into CA19.9-positive BxPc-3 pancreatic orthotopic tumor-bearing mice pretreated with or without clodronate liposomes for PET imaging and biodistribution studies. Inductively coupled plasma-optical emission spectrometry (ICP-OES) analysis was used to confirm delivery of gold nanoparticles to BxPc-3 pancreatic subcutaneous xenografts. RESULTS: Mice pretreated with clodronate liposomes in an orthotopic setting demonstrated decreased liver uptake at early time points (12.2 ± 2.3 % ID/g vs. 22.8 ± 3.8 % ID/g at 24 h) and increased tumor uptake at 120 h (13.8 ± 8.0 % ID/g vs. 6.0 ± 1.2 % ID/g). This allowed for delineation of orthotopic pancreatic xenografts in significantly more mice treated with clodronate (6/6) than in mice not treated with clodronate (2/6) or mice injected with gold nanoparticles labeled with a nonspecific antibody (0/5). CONCLUSIONS: The combination of clodronate liposomes and an active targeting antibody on the surface of gold nanoparticles allowed for PET/CT imaging of subcutaneous and orthotopic pancreatic xenografts in mice.
PURPOSE: Targeted delivery in vivo remains an immense roadblock for the translation of nanomaterials into the clinic. The greatest obstacle is the mononuclear phagocyte system (MPS), which sequesters foreign substances from general circulation and causes accumulation in organs such as the liver and spleen. The purpose of this study was to determine whether attaching an active targeting antibody, 5B1, to the surface of gold nanoparticles and using clodronate liposomes to deplete liver and splenic macrophages could help to minimize uptake by MPS organs, increase targeted delivery to CA19.9-positive pancreatic tumors, and enhance pancreatic tumor delineation. PROCEDURES: To produce the antibody-gold nanoparticle conjugate (Ab-AuNP), the Ab was conjugated to p-isothiocyanatobenzyl-desferrioxamine (p-SCN-DFO) and subsequently conjugated to NHS-activated gold nanoparticles. The Ab-AuNP was characterized by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Modified Lindmo assay was performed to assess binding affinity and internalization potential in vitro. The Ab-AuNP was radiolabeled with 89Zr and injected into CA19.9-positive BxPc-3 pancreatic orthotopic tumor-bearing mice pretreated with or without clodronate liposomes for PET imaging and biodistribution studies. Inductively coupled plasma-optical emission spectrometry (ICP-OES) analysis was used to confirm delivery of gold nanoparticles to BxPc-3 pancreatic subcutaneous xenografts. RESULTS: Mice pretreated with clodronate liposomes in an orthotopic setting demonstrated decreased liver uptake at early time points (12.2 ± 2.3 % ID/g vs. 22.8 ± 3.8 % ID/g at 24 h) and increased tumor uptake at 120 h (13.8 ± 8.0 % ID/g vs. 6.0 ± 1.2 % ID/g). This allowed for delineation of orthotopic pancreatic xenografts in significantly more mice treated with clodronate (6/6) than in mice not treated with clodronate (2/6) or mice injected with gold nanoparticles labeled with a nonspecific antibody (0/5). CONCLUSIONS: The combination of clodronate liposomes and an active targeting antibody on the surface of gold nanoparticles allowed for PET/CT imaging of subcutaneous and orthotopic pancreatic xenografts in mice.
Authors: Lei Cui; Sohyoung Her; Gerben R Borst; Robert G Bristow; David A Jaffray; Christine Allen Journal: Radiother Oncol Date: 2017-08-04 Impact factor: 6.280
Authors: Rachela Popovtzer; Ashish Agrawal; Nicholas A Kotov; Aron Popovtzer; James Balter; Thomas E Carey; Raoul Kopelman Journal: Nano Lett Date: 2008-12 Impact factor: 11.189
Authors: Muhammad U Farooq; Valentyn Novosad; Elena A Rozhkova; Hussain Wali; Asghar Ali; Ahmed A Fateh; Purnima B Neogi; Arup Neogi; Zhiming Wang Journal: Sci Rep Date: 2018-02-13 Impact factor: 4.996
Authors: Sijumon Kunjachan; Robert Pola; Felix Gremse; Benjamin Theek; Josef Ehling; Diana Moeckel; Benita Hermanns-Sachweh; Michal Pechar; Karel Ulbrich; Wim E Hennink; Gert Storm; Wiltrud Lederle; Fabian Kiessling; Twan Lammers Journal: Nano Lett Date: 2014-01-17 Impact factor: 11.189
Authors: Katherina P Farr; Daniel Moses; Koroush S Haghighi; Phoebe A Phillips; Claudia M Hillenbrand; Boon H Chua Journal: Cancers (Basel) Date: 2022-05-21 Impact factor: 6.575
Authors: Luman Liu; Prakash G Kshirsagar; Shailendra K Gautam; Mansi Gulati; Emad I Wafa; John C Christiansen; Brianna M White; Surya K Mallapragada; Michael J Wannemuehler; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Aliasger K Salem; Balaji Narasimhan; Maneesh Jain Journal: Theranostics Date: 2022-01-01 Impact factor: 11.600